CA2322663A1 - Induction of apoptotic or cytotoxic gene expression by adenoviral mediated gene codelivery - Google Patents

Induction of apoptotic or cytotoxic gene expression by adenoviral mediated gene codelivery Download PDF

Info

Publication number
CA2322663A1
CA2322663A1 CA002322663A CA2322663A CA2322663A1 CA 2322663 A1 CA2322663 A1 CA 2322663A1 CA 002322663 A CA002322663 A CA 002322663A CA 2322663 A CA2322663 A CA 2322663A CA 2322663 A1 CA2322663 A1 CA 2322663A1
Authority
CA
Canada
Prior art keywords
gene
cell
vector
promoter
bcl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002322663A
Other languages
English (en)
French (fr)
Inventor
Timothy J. Mcdonnell
Stephen G. Swisher
Bingliang Fang
Elizabeth M. Bruckheimer
Mona G. Sarkiss
Li Ji
Jack A. Roth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2322663A1 publication Critical patent/CA2322663A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002322663A 1998-03-11 1999-03-11 Induction of apoptotic or cytotoxic gene expression by adenoviral mediated gene codelivery Abandoned CA2322663A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7754198P 1998-03-11 1998-03-11
US60/077,541 1998-03-11
PCT/US1999/005359 WO1999046371A2 (en) 1998-03-11 1999-03-11 Induction of apoptotic or cytotoxic gene expression by adenoviral mediated gene codelivery

Publications (1)

Publication Number Publication Date
CA2322663A1 true CA2322663A1 (en) 1999-09-16

Family

ID=22138678

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002322663A Abandoned CA2322663A1 (en) 1998-03-11 1999-03-11 Induction of apoptotic or cytotoxic gene expression by adenoviral mediated gene codelivery

Country Status (4)

Country Link
EP (1) EP1070122A4 (de)
AU (1) AU762493B2 (de)
CA (1) CA2322663A1 (de)
WO (1) WO1999046371A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1266022B1 (de) * 2000-03-24 2008-10-22 Cell Genesys, Inc. Interne ribosomenzugangsstelle-enthaltende zell-spezifische adenovirale vektoren
WO2001092550A2 (en) * 2000-05-31 2001-12-06 Human Gene Therapy Research Institute Methods and compositions for efficient gene transfer using transcomplementary vectors
AU6069601A (en) * 2000-06-02 2001-12-17 Hiroshi Okamoto Pancreatic langerhans beta cell proliferation promoter and apoptosis inhibitor, and screening of candidate compounds for the e drugs
US6579522B1 (en) 2000-06-27 2003-06-17 Genvec, Inc. Replication deficient adenoviral TNF vector
EP1207205A1 (de) * 2000-11-20 2002-05-22 Crucell Holland B.V. Adenovirale Replikone
US20030086903A1 (en) 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer
CA2471719A1 (en) * 2001-12-31 2003-07-17 Dana-Farber Cancer Institute, Inc. Method of treating apoptosis and compositions thereof
JP4511108B2 (ja) 2002-05-31 2010-07-28 オンコリクス インコーポレイテッド ヒトプロラクチン拮抗剤−血管新生阻害剤融合蛋白質
CN100361710C (zh) 2004-06-07 2008-01-16 成都康弘生物科技有限公司 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用
US20080081354A1 (en) * 2006-10-02 2008-04-03 Cardiac Pacemakers, Inc. Devices, vectors and methods for inducible ischemia cardioprotection
WO2018093580A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
EP3704122B1 (de) 2017-11-03 2021-09-01 Amgen Inc. Fusionierte triazolagonisten des apj-rezeptors
WO2019213006A1 (en) 2018-05-01 2019-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the apj receptor
CN110174456B (zh) * 2019-06-11 2021-09-21 华润双鹤药业股份有限公司 一种测定肺表面活性物质蛋白的方法及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5297496A (en) * 1995-02-17 1996-09-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods of preparation and use of recombinant adenoviral vectors
DE19615803A1 (de) * 1996-04-20 1997-10-23 Boehringer Ingelheim Int CELO-Virus
AU5817299A (en) * 1998-09-10 2000-04-03 Uab Research Foundation, The Adenoviral vector encoding pro-apoptotic bax gene and uses thereof

Also Published As

Publication number Publication date
EP1070122A2 (de) 2001-01-24
WO1999046371A2 (en) 1999-09-16
AU762493B2 (en) 2003-06-26
EP1070122A4 (de) 2004-11-10
AU3183799A (en) 1999-09-27
WO1999046371A3 (en) 2000-08-24
WO1999046371A9 (en) 2000-02-17

Similar Documents

Publication Publication Date Title
US6899870B1 (en) Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery
AU742898B2 (en) Fas ligand compositions for treatment of proliferative disorders
AU762493B2 (en) Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery
PT1135469E (pt) Método melhorado para a produção e purificação de vectores adenovirais
AU762615B2 (en) Combination of radiotherapy and anti-angiogenic factors
US6251871B1 (en) P16 expression constructs and their application in cancer therapy
US20010011078A1 (en) DNA fragmentation factor involved in apoptosis
AU767880B2 (en) Multigene vectors
Gómez-Navarro et al. Gene therapy for carcinoma of the breast: Pro-apoptotic gene therapy
JP2005500247A (ja) ヒトｍｄａ−７に関わる処置方法
US6517828B1 (en) C-CAM as an angiogenesis inhibitor
US20060193832A1 (en) Use of the sodium iodine symporter to effect uptake of iodine
Shirakawa et al. Drug‐resistant human bladder‐cancer cells are more sensitive to adenovirus‐mediated wild‐type p53 gene therapy compared to drug‐sensitive cells
JP4117367B2 (ja) 腫瘍にあるサイクリンｇ１の発現を阻害する薬剤、その発現伝達体、およびベクター
US7625716B2 (en) Methods for assessing p19-Arf interactions in cMyc
US8187586B2 (en) Methods of inducing apoptosis in hyperproliferative cells
US6737052B1 (en) Induction of programmed cell death by N5 gene
US20010036929A1 (en) Xrcc3 is required for assembly of Rad51-complexes in vivo
US20020169126A1 (en) Compositions and methods for inactivating the Akt oncogene and/or activating the p38 pro-apoptotic gene
US20030138412A1 (en) Inhibition of tumor growth and metastasis by N5 gene
EP1208114A2 (de) Induktion der programmierten zelltod durch das n5 gene
Cerrato Mechanisms of Ad-p53 induced apoptosis in human malignant glioma
Brown Gene therapy for sporadic ovarian cancer
Lagace Genomic Organization of the X-linked Inhibitor of Apoptosis and Identification of a Novel Testis-specific Homologue

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead